ArticleNature medicine2023
GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders.
Abstract read
In one paragraph
Article in Nature medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Psychiatric effects of GLP-1 receptor agonists: A systematic review of emerging evidence.Diabetes, obesity & metabolism · 2026Pooled it
- Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial.The American journal of psychiatry · 2026Trial
- Once-Weekly Semaglutide in Adults With Daily Cigarette Use: A Randomized Clinical Trial.JAMA network open · 2026Trial
- Blood phosphatidylethanol measurements indicate GLP-1 receptor stimulation causes delayed decreases in alcohol consumption.Alcohol, clinical & experimental research · 2025Trial
- GLP-1 Receptor Agonist and GIP/GLP-1 Receptor Dual Agonist Therapeutics at the Intersection of Alcohol Use Disorder, Obesity, and Cardiometabolic Dysfunction.Biological psychiatry global open science · 2026Review
- Prescription Sequence Symmetry Analysis of Glucagon-Like Peptide-1 Receptor Agonists and Neuropsychiatric Conditions.Clinical pharmacology and therapeutics · 2026Article
- Article
- GLP-1-targeted therapies for alcohol and other substance use disorders: a new era on the horizon?The Journal of clinical investigation · 2026Article
- Association of GLP-1 Receptor Agonist Prescriptions and Alcohol Consumption in the National Institutes of Health's All of Us Cohort.Alcohol, clinical & experimental research · 2026Article
- Pharmacologic management of metabolic and alcohol-associated liver disease.Metabolism and target organ damage · 2026Article
- Semaglutide, tirzepatide, and retatrutide attenuate the interoceptive effects of alcohol in male and female rats.Psychopharmacology · 2026Article
- Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study.BMJ (Clinical research ed.) · 2026Article
- Glucagon-Like Peptide-1 Receptor Agonists and Alcohol Use: A Real-Word Observational Study in a Large, Integrated Health Care System.Biological psychiatry global open science · 2026Article
- Association of GLP-1 Receptor Agonist Prescriptions and Alcohol Consumption in the National Institutes of Health'smedRxiv : the preprint server for health sciences · 2026Article
- FGF21 analogue PF-05231023 on alcohol consumption and neuronal activity in the nucleus accumbens.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- GLP-1 agonists for smoking cessation and post-cessation weight management: A systematic review and meta-analysis of randomized trials.Tobacco induced diseases · 2026Review
- Effect of dietary stimulation on acute changes in GLP-1, alcohol responses, craving, and attentional bias: a randomized, placebo-controlled laboratory study.Psychopharmacology · 2025Article
- Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease.Nature reviews. Gastroenterology & hepatology · 2025Review
- Effects of glucagon-like peptide-1 receptor agonists on alcohol consumption: a systematic review and meta-analysis.EClinicalMedicine · 2025Article
- Crosstalk between alcohol use disorder and obesity: two sides of the same coin?Molecular psychiatry · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Lorenzo LeggioClinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore, MD, USA. lorenzo.leggio@nih.gov.ORCID 0000-0001-7284-8754
Christian S HendershotBowles Center for Alcohol Studies and Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0002-5328-2035
Mehdi FarokhniaClinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore, MD, USA.ORCID 0000-0003-0902-4212
Anders Fink-JensenPsychiatric Centre Copenhagen, Mental Health Services in the Capitol Region of Denmark, Copenhagen, Denmark.ORCID 0000-0001-7143-1236
Mette Kruse KlausenPsychiatric Centre Copenhagen, Mental Health Services in the Capitol Region of Denmark, Copenhagen, Denmark.ORCID 0000-0002-9300-470X
Joseph P SchachtDepartment of Psychiatry, University of Colorado School of Medicine, Aurora, CO, USA.
W Kyle SimmonsDepartment of Pharmacology & Physiology, Oklahoma State University Center for Health Sciences, Tulsa, OK, USA.ORCID 0000-0002-0399-9003
Funding
A pharmacogenetic human laboratory investigation of brexpiprazole in Alcohol Use DisorderR01AA027765 · NIAAA · UNIVERSITY OF COLORADO DENVER · PI SCHACHT, JOSEPH P. · 2019 to 2023
$2.4MCOMT inhibition as a potential therapeutic target among individuals with comorbid Alcohol Use Disorder and Attention-Deficit/Hyperactivity DisorderR01AA026859 · NIAAA · UNIVERSITY OF COLORADO DENVER · PI SCHACHT, JOSEPH P. · 2019 to 2023
$1.8MEffects of Semaglutide on Nicotine Intake and Smoking LapseR21DA047663 · NIDA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HENDERSHOT, CHRISTIAN S · 2019 to 2021
$461kHuman Laboratory Screening of Semaglutide for Alcohol Use DisorderR21AA026931 · NIAAA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HENDERSHOT, CHRISTIAN S · 2019 to 2021
$440kAn exploratory randomized controlled trial of the effects of oral semaglutide on alcohol craving and consumptionR21AA031146 · NIAAA · UNIVERSITY OF COLORADO DENVER · PI SCHACHT, JOSEPH P. · 2023 to 2023
$429kIntramural NIH HHS Z99 DA999999NIAAA NIH HHS R01 AA026859NIAAA NIH HHS R01 AA027765NIAAA NIH HHS R21 AA026931NIAAA NIH HHS R21 AA031146NIDA NIH HHS R21 DA047663
Abstract
PubMed holds no abstract for this paper.
Indexed as
Diabetes Mellitus, Type 2Substance-Related DisordersEthanolGlucagon-Like Peptide-1 Receptor AgonistsHumansEthanolGlucagon-Like Peptide-1 Receptor Agonists
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.